Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)’s traded shares stood at 0.77 million during the last session, with the company’s beta value hitting 0.72. At the close of trading, the stock’s price was $24.49, to imply an increase of 1.58% or $0.38 in intraday trading. The CPRX share’s 52-week high remains $26.16, putting it -6.82% down since that peak but still an impressive 39.77% since price per share fell to its 52-week low of $14.75.
Analysts have given a consensus recommendation of Buy for Catalyst Pharmaceuticals Inc (CPRX), translating to a mean rating of 1.12. Of 3 analyst(s) looking at the stock, 0 analyst(s) give CPRX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.54.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) trade information
After registering a 1.58% upside in the last session, Catalyst Pharmaceuticals Inc (CPRX) has traded red over the past five days. The 5-day price performance for the stock is 0.49%, and 5.61% over 30 days. With these gigs, the year-to-date price performance is 17.35%.
The extremes give us $32 and $35 for target low and target high price respectively. As such, CPRX has been trading -42.92% off suggested target high and -30.67% from its likely low.
Catalyst Pharmaceuticals Inc (CPRX) estimates and forecasts
The rating firms project that company’s revenue will grow 14.09% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is 140.42M. Meanwhile, for the current quarter, a total of 8 analyst(s) estimate revenue growth to 138.56M.Earnings reports from the last fiscal year show that sales brought in 122.71M and 128.69M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 14.43% before jumping 7.66% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 34.27% for the past 5-year period. While 2025 is set for a 16.67% return in earnings, projections for the next 5 years are at 12.70% annually.
CPRX Dividends
Catalyst Pharmaceuticals Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with 9.13 million shares, or about 7.7232% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $141.38 million.
We also have iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Catalyst Pharmaceuticals Inc (CPRX) shares. Going by data provided on Mar 31, 2025 , iShares Trust-iShares Core S&P Small-Cap ETF holds roughly 6.93 shares. This is just over 5.68% of the total shares, with a market valuation of $169.78 million. Data from the same date shows that the other fund manager holds a little less at 3.52, or 2.89% of the shares, all valued at about 86.27 million.
